Purpose of Study
Evaluate the potential of dalcetrapib to reduce cardiovascular morbidity and mortality (cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction (MI) and non-fatal stroke) in subjects with a documented recent ACS and the AA genotype at variant rs 1967309 in the ADCY9 gene.
In Follow up
Are at least 45 years old, have had a heart attack within the past 3 months, and have the AA genotype.
Duration of Participation
Approximately 54 months
Contact Name: Research Department
Contact Phone: 515-633-3842